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Background/Aims: Because of rarity, role of chemotherapy of bladder adenocar-
cinoma are still unidentified. Therefore, we performed a retrospective analysis of 
the clinical features and chemotherapy outcomes of bladder adenocarcinoma. 
Methods: Eligible patients for this retrospective analysis were initially diagnosed 
with bladder adenocarcinoma and presented with a clinically no other primary 
site of origin. The collected data included age, gender, performance status, stage, 
hemoglobin, albumin, initial date of diagnosis, treatment modality utilized, 
response to treatment, presence of relapse, last status of patient, and last date of 
follow-up.
Results: We retrospectively reviewed 29 patients, who were treated with chemo-
therapy for bladder adenocarcinoma at 10 Korean medical institutions from 2004 
to 2014. The median age of patients was 58 years (range, 17 to 78) and 51.7% of the 
patients were female. Urachal adenocarcinoma was identified in 15 patients. Of 
27 symptomatic patients, 22 experienced gross hematuria. Twelve patients were 
treated with 5-f luorouracil based chemotherapy, f ive were gemcitabine based, 
three were taxane and others. Thirteen of them achieved complete response (10.3%) 
or partial response (34.5%). Median progression-free survival (PFS) and overall 
survival (OS) for all patients were 10.6 months (95% confidence interval [CI], 9.5 
to 11.6) and 24.5 months (95% CI, 1.2 to 47.8), respectively. The cases of urachal ad-
enocarcinoma exhibited worse tendency in PFS and OS (p = 0.024 and p = 0.046, 
respectively).
Conclusions: Even though bladder adenocarcinoma had been observed moderate 
effectiveness to chemotherapy, bladder adenocarcinoma is a highly aggressive 
form of bladder cancer. PFS and OS were short especially in urachal carcinoma. 
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INTRODUCTION
Primary adenocarcinoma of the bladder is a malig-
nant neoplasm derived from urothelium of the bladder 
showing histologically pure glandular differentiation [1]. 
Primary adenocarcinoma of the bladder is a rare malig-
nancy, representing only 0.5% to 2.5% of all malignant 
bladder neoplasm [2,3]. This tumor is more common in 
males with approximate mean age of 50 to 60 years [4,5]. 
Generally, the tumor is very aggressive, with metastatic 
disease reported in up to 25% to 40% of patients at the 
time of diagnosis [6,7]. The pathogenesis of primary ad-
enocarcinoma of the urinary bladder has not been fully 
elucidated. Intestinal metaplasia has been speculated to 
be a precursor lesion [8], largely because it is often seen 
in mucosa adjacent to primary adenocarcinoma of the 
urinary bladder. The diagnosis of a primary adenocar-
cinoma of the bladder should only be made when the 
carcinoma exhibits pure glandular differentiation. In 
many cases of adenocarcinoma of the bladder, the most 
important and the most difficult task is to differentiate 
these tumors from metastatic adenocarcinoma from 
other organs such as colon, lung, prostate, breast, and 
uterus. The most frequent secondary tumor involving 
the urinary bladder is adenocarcinoma of the colon, 
which morphologically resembles adenocarcinoma of 
the urinary bladder (enteric type). Because of its rarity, 
role of chemotherapy for advanced bladder adenocar-
cinoma is still questionable. Therefore, we performed 
a retrospective analysis of the clinical features and che-
motherapy outcomes of advanced bladder adenocarci-
noma to evaluate the clinical findings at presentation, 
treatment modality and outcome, overall survival (OS) 
and progression-free survival (PFS) and prognostic fac-
tors.
METHODS
Patients
We retrospectively reviewed the patients diagnosed with 
bladder adenocarcinoma at 10 Korean medical centers 
from 2005 to 2014. All the patients diagnosed adenocar-
cinoma through the tissue biopsy, and should have been 
treated at least one cycle of palliative chemotherapy for 
metastatic lesion. Adjuvant treatment after operation 
was excluded. And the patients who had favored prima-
ry colon, lung, or ovary lesion were excluded from the 
study. 
Unified case report forms were provided to partic-
ipating institutions. The collected data included age, 
gender, performance status, presenting symptom, stage, 
location of metastatic lesions, hemoglobin, initial date 
of diagnosis, and chemotherapy regimen utilized. We 
also obtained data regarding time to relapse, relation-
ship with primary site and relapsing site, salvage treat-
ment modality, and response and survival rates of sal-
vage treatment. Responses were classified according 
to the Response Evaluation Criteria in Solid Tumors 
criteria. This study was approved by the Institutional 
Review Board of Dong-A University Hospital (DAUH-
IRB-14-108). 
Statistical analysis
PFS was estimated from the date treatment began to the 
date when disease progression was recognized, or the 
date of the last follow-up visit, or the date of death. OS 
was calculated from the first day of diagnosis with meta-
static or recurrent disease to the date of death or the last 
follow-up evaluation. OS and PFS were estimated using 
the Kaplan-Meier product-limit method. Survival rates 
were compared for statistical differences using log-rank 
analysis. The Cox regression model was used for multi-
variate analysis with factors that had been used in uni-
variate (log rank) analysis of OS and PFS. All statistical 
analyses were performed using the IBM SPSS version 
20.0 (IBM Co., Armonk, NY, USA). p value less than 0.05 
was considered statistically significant and all p values 
corresponded to two-sided significance tests.
RESULTS
Patients’ characteristics
Between February 2005 and June 2014, a total of 29 pa-
tients from 10 different institutions in Korea were in-
cluded. Diagnosis of bladder adenocarcinoma was made 
by examination of a partial or radical cystectomy speci-
men in 21 cases and by bladder biopsy in eight.
A list of patients and tumor characteristics is shown in 
Tables 1 and 2. The median age of patients was 58 years 
(range, 17 to 78) and 41.4% was over 60 years. Typical-
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ly, 51.7% of the patients were female. Of 27 symptomatic 
patients, 22 and six patients experienced gross hema-
turia and palpable mass, respectively. Other presenting 
symptoms included abdominal distension, dysuria/
frequency, and abdominal pain. The median level of 
hemoglobin was 12.1 g/dL (range, 6.9 to 15.4). The most 
frequent pathological diagnosis was urachal adenocarci-
noma (48.3%) followed by nonspecific adenocarcinoma 
and mucinous adenocarcinoma (13.8%), adenocarcino-
ma of enteric type and adenocarcinoma with signet ring 
cell (6.9%), well-differentiated adenocarcinoma (3.4%), 
and infiltrating adenocarcinoma (3.4%). Patients were 
initially presented with metastatic lesion or in relapsed 
state after definitive treatment. Eight patients (25.6%) 
had no history of prior operation, and 21 patients had 
previously received curative (48.3%) or palliative (24.1%) 
operation. Fifteen patients presented with initially dis-
tance metastatic lesions. Twelve patients had two or 
more metastatic sites of the lung (51.7%), peritoneum 
(41.4%), ovary (20.7%), and lymph nodes (13.8%) as the 
most common sites.
Palliative chemotherapy and response 
Patients were treated with several variable chemother-
apy regimens (Table 3). Usual chemotherapeutic regi-
mens for urothelial cell carcinoma—GP (gemcitabine 
+ cisplatin), MVAC (methotrexate + vinblastine + adri-
amycin + cisplatin), MVP (methotrexate + vinblastine 
+ cisplatin)—were used in nine patients. Among them, 
partial response (PR) was observed in four patients. 
The 5-fluorouracil (5-FU) based chemotherapeutic 
regimens—FP (5-FU + cisplatin), FAP (5-FU + adriamycin 
+ cisplatin), FOLFOX (oxaliplatin + leucovorin + 5-FU), 
FEP (5-FU + epirubicine + cisplatin)—were used in 12 
patients. Of the 12 patients, PR was observed in five pa-
tients. The three patients treated with taxane and plati-
num combination regimen experienced two CRs.
Table 1. Patients’ characteristics (n = 29)
Characteristic No. (%)
Sex
Male 14 (48.3)
Female 15 (51.7)
Age, yr
Median (range) 58 (17–78)
≥ 60 12 (41.4)
< 60 17 (58.6)
Hemoglobin, g/dL 
≥ 12 16 (55.2)
< 12 13 (44.8)
Diagnosis
Urachal adenocarcinoma 15 (51.7)
Adenocarcinoma nonspecific 4 (13.8)
Mucinous adenocarcinoma 4 (13.8)
Adenocarcinoma of enteric type 2 (6.9)
Adenocarcinoma with signet-ring cell 2 (6.9)
Adenocarcinoma, well differentiated 1 (3.4)
Infiltrating adenocarcinoma 1 (3.4)
Previous operation 
Curative 14 (48.3)
Palliative 7 (24.1)
No operation 8 (25.6)
Metastatic presentation
Relapse 14 (48.3)
Initial metastasis 15 (51.7)
Organ of metastasis
Lung 15 (51.7)
Peritoneum 12 (41.4)
Ovary 6 (20.7)
Lymph node 4 (13.8)
Bone 3 (10.3)
Bladder/ureter 2 (6.9)
Colon/rectum 2 (6.9)
Liver 1 (3.4)
Table 2. Symptoms of advanced bladder adenocarcinoma (n = 29)
Variable No. (%)
Hematuria 22 (75.9)
Palpable mass 6 (20.7)
Abdominal distension 5 (17.2)
Dysuria/frequency 4 (13.8)
Abdominal pain 3 (10.3)
Fever 1 (3.4)
Vaginal spotting 1 (3.4)
Dyspnea 1 (3.4)
No subjective symptom 2 (6.9)
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Survivals and prognostic factor analysis
During the median follow-up period of 12.7 months 
(range, 1.6 to 79.7) progression was seen in 21 patients, 
while 13 patients (25.7%) died. Median PFS and OS for 
all patients were 10.6 months (95% confidence interval 
[CI], 9.5 to 11.6) and 24.5 months (95% CI, 1.2 to 47.8), re-
spectively (Fig. 1). Patients with nonurachal adenocarci-
nomas had a better median PFS of 20.6 months when 
compared with 10.4 months of patients with urachal 
adenocarcinomas (p = 0.024) (Fig. 2). In median OS, non-
urachal adenocarcinomas patients who did not reached 
median OS were better than 16.3 months of urachal ade-
nocarcinomas (p = 0.046) (Fig. 3). The clinical factors pre-
dicting reduced in PFS and OS was subtype of adenocar-
cinoma especially in urachal adenocarcinoma (Table 4). 
DISCUSSION
Our study evaluated the efficacy of palliative chemo-
therapy for adenocarcinoma of bladder and until date, it 
is one of the largest reports on the efficacy of palliative 
chemotherapy for the treatment of advanced bladder 
adenocarcinoma, even though the number of patients 
was relatively small and retrospective analysis. 
Usually it has been reported that male is predom-
inant in bladder adenocarcinoma [4,5,9]. Because of 
small study population, numbers of female was a lit-
tle bite larger than male in this study. Nontransitional 
cell urothelial carcinoma including adenocarcinoma, 
squamous cell carcinoma, or small cell carcinoma is an 
uncommon tumor and accounts for only 5% to 10% of 
urothelial cancers [10,11]. Thus, the clinical experience 
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Figure 1. Median progression-free survival (PFS) and overall 
survival (OS) for all patients were 10.6 months (95% confi-
dence interval [CI], 9.5 to 11.6) and 24.5 months (95% CI, 1.2 
to 47.8).
Table 3. Chemotherapy result of advanced bladder adenocarcinoma (n = 29)
Chemotherapy Number CRa PRa SD PD NE
GP 5 2 1 2
MVAC 3 2 1
MVP 1 1
FP 7 3 3 1
FOLFOX 1 1
FAP 2 1 1
FEP 1 1
5-FU single 1 1
EP 3 1 1 1
Taxane/platinum 3 2 1
Pemetraxed 1 1
Sunitinib 1
CR, complete response; PR, partial response; SD, stable disease; PD, progression of disease; NE, not evaluable; GP, gemcitabine 
+ cisplatin; MVAC, methotrexate + vinblastine + adriamycin + cisplatin; MVP, methotrexate + vinblastine + cisplatin; FP, 5-FU 
+ cisplatin; FOLFOX, oxaliplatin + leucovorin + 5-FU; FAP, 5-FU + adriamycin + cisplatin; FEP, 5-FU + epirubicine + cisplatin; 
5-FU, 5-fluorouracil; EP, etoposide + cisplatin.
aCR + PR = 13 (44.8%).
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with chemotherapy is limited, and to date, treatment 
recommendations have largely been derived based on 
case reports and small series [11-14]. Galsky et al. [12] re-
ported the chemotherapeutic outcomes for 20 patients 
with nontransitional cell carcinoma of the urothelial 
tract (11 patients with adenocarcinomas, eight patients 
with squamous cell carcinomas, and one patient with 
small cell carcinoma), using a chemotherapeutic reg-
imen consisting of palitaxel, cisplatin, and ifosfamide 
with mesna. In the reported study, seven patients had a 
CR or PR, with an objective response rate of 35% (36% in 
adenocarcinoma). The median OS was 24.8 months in 
patients with adenocarcinomas and 9 months in those 
with squamous cell carcinomas. A study by Hong et al. 
[4] showed an objective response rate of 36% to various 
first-line chemotherapeutic regimens and a median 
OS of 47 months in 14 patients with adenocarcinoma. 
Siefker-Radtke [13] reported median survival from rec-
ognition of metastatic disease as 24 months in 26 pa-
tients in whom metastases ultimately developed. Che-
motherapy with various regimens for metastatic disease 
produced only four significant responses, including 
three of nine patients treated with 5-FU and cisplatin 
containing regimens. As per our result, 44.8 % of over-
all response rate was higher and 24.5 months of median 
survival was comparable with prior studies (Table 5). 
When we choose the chemotherapeutic regimen, we 
don’t have any evidence based consensus regimen for 
bladder adenocarcinoma. Transitional cell cancers 
(TCCs) are treated with gemcitabine-platinum combi-
nation, MVAC, or MVP regimens, while adenocarcino-
ma is usually treated with 5-FU based combination che-
motherapy. In this study, TCC focused treatment and 
adenocarcinoma focused treatments were effective and 
no differences in PFS and OS. Considering an objective 
response rate of 39% to 65% to the MVAC or gemcit-
abine-platinum regimens in advanced transitional cell 
carcinoma [15-17], the objective response of palliative 
chemotherapy in advanced bladder adenocarcinoma is 
comparatively lower than transitional cell carcinoma. 
However, the OS of 24.5 months of this study showed 
comparable survival results with previous studies re-
garding transitional cell carcinoma patients [18,19]. 
We observed that patients with nonurachal adeno-
carcinomas had a better median PFS of 20.6 months 
when compared with 10.4 months in patients with 
urachal adenocarcinomas (p = 0.024) in the metastatic 
palliative chemotherapy setting. However, it remains 
unclear whether the survival of patients with urachal 
adenocarcinoma differs from that of patients with non-
urachal adenocarcinomas itself. Wright et al. [20] found 
that urachal cancer had a significantly better prognosis 
than nonurachal cancer. Compared to those with non-
urachal tumors, patients with urachal adenocarcinoma 
were more likely to be younger (median age, 56 years vs. 
69 years, p < 0.001) and female (45% vs. 36%, p = 0.02). 
Urachal lesions were less likely to be high grade (35% vs. 
66%, p < 0.001), but more likely to involve distant me-
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Figure 2. Patients with nonurachal adenocarcinomas had 
a better median progression-free survival (PFS) of 20.6 
months when compared with 10.4 months in patients with 
urachal adenocarcinomas (p = 0.024).
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Figure 3. Patients with nonurachal adenocarcinomas had a 
better median overall survival (OS) when compared with 16.3 
months in patients with urachal adenocarcinomas (p = 0.046).
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tastases (30% vs. 15%, p < 0.001). While Mostofi et al. [21] 
reported that urachal adenocarcinomas were associat-
ed with a significantly worse prognosis. The 17 tumors 
that were probably urachal in origin were characterized 
clinically by a more unfavorable course, all but three of 
the patients having died in less than 5 years. The poor 
prognosis of the urachal tumor is believed to be due to 
incomplete removal, for these tumors tend to spread 
along the remnants of the pre-existing urachal tract, not 
only in the bladder wall but in the anterior abdominal 
wall as well. Dandekar et al. [22] and Zhang et al. [9] stat-
ed the difference between urachal adenocarcinoma and 
Table 4. Prognostic factor analysis of survivals
Variable
PFS OS 
Median, mon  p valuea Median, mon p valuea
Sex 0.755 0.382
Male 10.1 16.3
Female 13.2 -b
Age, yr 0.205 0.374
≥ 60 10.4 12.9
< 60 13.2 24.5
Initial status 0.654 0.725
Relapsed 10.1 23.5
Metastatic 13.2 38.4
Hemoglobin, g/dL 0.101 0.835
≥ 12 14.3 23.5
< 12 10.4 12.9
Hematuria 0.074 0.478
(+) 10.6 23.5
(–) 6.1 -b
Lung involvement 0.905 0.821
(+) 10.8 23.5
(–) 10.6 16.3
Peritoneal seeding 0.117 0.647
(+) 7.2 20.7
(–) 14.3 38.4
5-FU included regimens 0.158 0.486
(+) 10.1 16.3
(–) 14.3 23.5
Urinary tract regimensc 0.827 0.545
(+) 14.3 23.5
(–) 10.4 20.7
Subtype 0.024 0.046
Urachal adenocarcinoma 10.4 16.3
The others 20.6 -b
PFS, progression-free survival; OS, overall survival; 5-FU, 5-fluorouracil.
aBy log-rank test for univariate analysis.
bDid not reached median value.
cGemcitabine/cisplatin, MVAC (methotrexate + vinblastine + adriamycin + cisplatin), or MVP (methotrexate + vinblastine + cis-
platin).
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nonurachal adenocarcinoma as not significant. These 
different results between studies about prognostic val-
ue of urachal and nonurachal adenocarcinoma might 
be depending on included different proportion of early 
stage, treatment option (operability), and comorbidity of 
patients.
This study has several limitations. This study was a 
retrospective analysis. Therefore it could have possibili-
ty of selection bias, insufficiency of medical records, and 
heterogeneity of treatment. The number of patients en-
rolled in the study was too small to evaluate efficacy of 
chemotherapy and analyze prognostic factors. Neverthe-
less, considering the relatively uncommon incidence of 
the disease, this is one of the largest data sets reporting 
clinical results of chemotherapy and could have an im-
portance of histological types as a prognostic factor in 
advanced bladder adenocarcinoma. 
Prospective trials are warranted to make a clinically 
meaningful improvement in palliative chemotherapy in 
the treatment of advanced bladder adenocarcinomas.
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